International Multicentric Observational Study to Characterize Subpopulations of Patients With Autism Spectrum Disorder

Launched by STALICLA SA · Oct 18, 2022

Keywords

ClinConnect Summary

This clinical trial is looking to better understand autism spectrum disorder (ASD) by identifying different groups of patients who might respond best to a specific medication. Researchers want to gather information about biological and clinical markers, which are signs or indicators that could help in tailoring treatments for individuals with ASD. The study is currently recruiting participants, and it is open to individuals aged between 4 and 17 years.

To be eligible for the trial, participants must have a confirmed diagnosis of ASD and have health records from their early childhood. It's also important that they have a parent or caregiver who can provide information about their health. Participants should be willing to take part in the study and give their consent. However, those who have had a recent fever or significant illness may not be able to join. If you or your child are considering participation, you can expect to provide health information and be part of a study that aims to improve understanding and treatment options for ASD.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Participants previously diagnosed with ASD (DSM-5)
• • Available well-documented health records within the first 2 years of life
• • Participants must have a parent or reliable caregiver who agrees to provide information about the participant
• • Participants willing and consenting or assenting to participate.
• Exclusion Criteria:
• • Episode of fever (i.e. ≥100.5 °F or ≥ 38 °C) or clinically significant illness without fever (as judged by the investigator), within 10 days before any study assessment.
• • If the investigator assesses any unwillingness or any medical condition that may prevent the subject from completing this study.